sintx
-
SINTX Technologies Announces Its New Utah Armor Facility Is Fully Operational
Facility will produce high-performance ceramic armor products for personnel, aircraft, and vehicles
-
SINTX Technologies Announces Closing of $12.0 Million Public Offering
SINTX Technologies Announces Closing of $12.0 Million Public Offering
-
NATIONAL INSTITUTES OF HEALTH AWARDS GRANT TO SINTX TECHNOLOGIES FOR DEVELOPMENT OF 3D PRINTED ANTIMICROBIAL TRAUMA DEVICE
SINTX announced a Phase I grant of $275k awarded by the National Institutes of Health (NIH) to develop…
-
SINTX ANNOUNCES MILESTONES IN THE DEVELOPMENT AND TESTING OF ANTIPATHOGENIC FABRICS
SINTX Technologies announced new results on the development of manufacturing technologies to produce fabrics impregnated with SINTX silicon…
-
NIH AWARDS SINTX TECHNOLOGIES PHASE 1 GRANT FOR SN-PEEK 3D PRINTED SPINAL IMPLANTS
NATIONAL INSTITUTE OF HEALTH AWARDS SINTX TECHNOLOGIES PHASE 1 GRANT FOR SN-PEEK 3D PRINTED SPINAL IMPLANTS
-
NIH AWARDS SINTX TECHNOLOGIES PHASE 1 GRANT FOR SN-PEEK 3D PRINTED SPINAL IMPLANTS
SINTX Technologies, Inc., an original equipment manufacturer of advanced ceramics, announced today a Phase 1 grant of $308,301…
-
SINTX ARMOR SHIPS FIRST ORDER AND PREPARES FOR MOVE TO UTAH
SINTX Technologies, Inc., an original equipment manufacturer of advanced ceramics, announced today that its newly created and wholly-owned…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
